Updates are available Correction dated 2023-05-08
Click to view Correction: https://doi.org/10.1007/s10384-023-00996-7
-
Authors
Mori, Ryusaburo
Honda, Shigeru
Gomi, Fumi
Tsujikawa, Akitaka
Koizumi, Hideki
Ochi, Haruka
Ohsawa, Shino
Okada, Annabelle Ayame
,
-
Funding
Funding for this research was provided by:
F. Hoffmann-La Roche Ltd. (F. Hoffmann-La Roche Ltd.)
Genentech, Inc (Genentech, Inc)
Chugai Pharmaceutical Co. (Chugai Pharmaceutical Co.)
- License Information
-
More Information
Article History
Received: 3 September 2022
Accepted: 24 February 2023
First Online: 11 April 2023
Change Date: 8 May 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10384-023-00996-7
Declarations
:
: R. Mori, Consulting fees (Novartis, Chugai, Boehringer Ingelheim), Payment or honoraria for Writing, speakers bureau (Novartis, Nikon), Payment or honoraria for speakers bureau (Bayer, Santen, Senju, JFC Sales Plan, Chugai); S. Honda, None; F. Gomi, Grants to the author’s institution (Senju, Santen), Consulting fees (Senju), Payment or honoraria for speakers bureau, lectures (Chugai), Payment or honoraria for Speakers bureau (Novartis, Bayer, Santen, Senju), Advisory Board (Senju, Boehringer Ingelheim) ; A. Tsujikawa, Grants or contracts (Santen, Senju, Novartis), Consulting fees (Santen, Senju), Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Santen, Senju, Novartis, Bayer, Chugai), Payment for expert testimony (Senju, Chugai); H. Koizumi, Payment for lectures (Chugai, Roche); H. Ochi, Employee (Chugai); S. Ohsawa, Employee (Chugai); A. A. Okada, Consulting fees (Chugai, Bayer, Novartis, Apellis, Biocon), Payment or honoraria for Speakers bureau (Chugai, Santen), Payment or honoraria for Writing, speakers bureau (Novartis, Bayer, Senju), Stock or stock options (Hemera Biosciences).
Free to read: This content has been made available to all.
